Stocks · News reference

Moleculin Biotech Announces Its Miracle Trial Reports 37% Blinded Complete Remission In Venetoclax-failed R/R AML Patients

Jul 31, 2026, 12:10 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:48 PMBenzinga Newsdesk
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Read original at benzinga
MBRX
SEC EDGARAug 14, 2026, 12:30 PMSEC EDGAR
8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-08-14 AccNo: 0001437749-26-027835 Size: 380 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
MBRX
BenzingaJul 31, 2026, 5:37 PMVandana Singh
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.
Read original at benzinga
ABBV MBRX
BenzingaJul 31, 2026, 4:48 PMBenzinga Newsdesk
Moleculin Biotech shares are trading lower after the company announced it priced a $9.3 million public offering.
Read original at benzinga
MBRX